Allegro Ophthalmics LLC

34 articles about Allegro Ophthalmics LLC

• U.S. Phase 2 Study Published in OSLI Retina Highlights the Safety and Efficacy of Risuteganib in Patients with Dry Age-Related Macular Degeneration

  8/3/2021

  Allegro Ophthalmics today announced that the results of the company’s U.S. Phase 2a risuteganib non-exudative age-related macular degeneration (dry AMD) study are published in Ophthalmic Surgery, Lasers, and Imaging (OSLI) Retina.

• Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease

  7/24/2021

  Allegro Ophthalmics, LLC announced that all primary and secondary endpoints of an ex-U.S. vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease were met.

• Allegro Ophthalmics to Present the Results of ALG-1007 Ex-U.S. Phase 2 Clinical Trial for Dry Eye Disease at the 2021 ASCRS ASOA Annual Meeting

  7/19/2021

  Allegro Ophthalmics , LLC today announced that the results of the company’s second ALG-1007 ex-U.S. clinical trial for the treatment of dry eye disease (DED) will be presented during the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting being held July 23-27 in Las Vegas, NV.

• William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors

  6/22/2021

  William J. Link, PhD, Named Chairman of Allegro Ophthalmics’ Board of Directors Executive Team Strengthened with the Appointment of Stephanie Yee as Vice President of Finance

• Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting

  4/27/2021

  Allegro Ophthalmics , LLC, a privately held biopharmaceutical company focused on the development of novel integrin regulating therapies for the treatment of ocular diseases, today announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

• Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics

  9/21/2020

  Agreement Includes Global Rights for Risuteganib, An Investigational Treatment Expected to Help Reverse Vision Loss Due to Dry AMD, A Significant Unmet Medical Need

• Allegro Ophthalmics to Present Clinical Research on the Company’s Novel Integrin-Regulating Portfolio at the American Academy of Ophthalmology Annual Meeting

  10/8/2019

  AAO 2019 To Feature Multiple Presentations by Leading Experts on Allegro’s Dry Age-Related Macular Degeneration and Dry Eye Disease Assets

• Allegro Ophthalmics to Present the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the 19th EURETINA Congress and The Retina Society 2019 Annual Meeting

  9/3/2019

  Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin functions for the treatment of ocular diseases, today announced that the results of its U.S. Phase 2 study evaluating risuteganib (Luminate®) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during the 19th European Society of Retina Specialists (EURETINA) Congress

• Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019

  7/24/2019

  Risuteganib Met Visual Acuity Primary Endpoint with Statistical Significance in U.S. Phase 2 Trial

• Allegro Ophthalmics Announces Positive Topline Vision Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry Age-Related Macular Degeneration

  6/4/2019

  U.S. Phase 2 Trial Met Primary Endpoint with Statistical Significance

• Allegro Ophthalmics Announces Positive Results of Ex-U.S. Proof-of-Concept Trial with Integrin Inhibitor ALG-1007 for Dry Eye Disease

  5/14/2019

  Results of the Trial Suggest that ALG-1007 is Well-Tolerated and Demonstrates a Dose Response with Improvement as Early as Two Weeks

• Allegro Ophthalmics Expands Its Anti-Integrin Portfolio with New Front-of-the-Eye Drug Candidate ALG-1007 for the Treatment of Dry Eye Disease

  4/25/2019

  Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, today announced the expansion of the company’s anti-integrin portfolio with the new front-of-the-eye-drug candidate ALG-1007

• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Allegro Ophthalmics Prepares To Take Lead Compound Risuteganib To Phase 3, Appoints New CEO

  8/21/2018

  Hampar Karageozian, Co-Founder and Former CEO, Named Executive Chairman

• Allegro Ophthalmics LLC Announces Positive Topline Results From DEL MAR Phase IIb Stage 2 Trial Evaluating Luminate In Patients With Diabetic Macular Edema

  8/9/2017

• Allegro Ophthalmics LLC Secures $10.7 Million In Private Financing

  7/24/2017

• Allegro Ophthalmics LLC Names Melvin Sarayba, MD, Vice President Of Clinical Affairs

  3/7/2017

• Allegro Ophthalmics LLC Completes Enrollment In DEL MAR Phase IIb, Stage 2 Clinical Trial Of Luminate For The Treatment Of Diabetic Macular Edema

  12/15/2016

• William J. Link, PhD, Joins Allegro Ophthalmics LLC’ Board Of Directors

  11/21/2016

• Allegro Ophthalmics LLC Announces Positive Topline Results From DEL MAR Phase 2b Trial Evaluating Luminate In Patients With Diabetic Macular Edema

  10/13/2016